title: Electrochemically driven drug metabolism via cytochrome P450 2C9 isozyme microsomes with cytochrome P450 reductase and indium tin oxide nanoparticle composites.
abstract: We describe herein an electrochemically driven drug metabolism strategy based on nanocomposites that integrate cyt P450 2C9 (CYP2C9) isozyme microsomes with cyt P450 reductase (CPR), indium tin oxide (ITO) nanoparticles and chitosan (CS). This novel bioelectronic system enables monitoring of the drug metabolism and enzyme inhibition.
authors: School of Chemistry and Chemical Engineering, Southeast University Jiangning, Nanjing 211189, People's Republic of China.
authors: Xuan
authors: X
authors: Xu
authors: Wei
authors: W
authors: Wei
authors: Minghe
authors: M
authors: Huang
authors: Li
authors: L
authors: Yao
authors: Songqin
authors: S
authors: Liu
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002244:Carbon / Q000737:chemistry; D048271:Chitosan / Q000737:chemistry; D065729:Cytochrome P-450 CYP2C9; D055664:Electrochemical Techniques; D004566:Electrodes; D004791:Enzyme Inhibitors / Q000737:chemistry; D006801:Humans; D053768:Metal Nanoparticles / Q000737:chemistry*; D008861:Microsomes / Q000378:metabolism*; D009251:NADPH-Ferrihemoprotein Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D017971:Tin Compounds / Q000737:chemistry*
chemical_list: D004791:Enzyme Inhibitors; D004364:Pharmaceutical Preparations; D017971:Tin Compounds; C109984:indium tin oxide; D002244:Carbon; D048271:Chitosan; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D009251:NADPH-Ferrihemoprotein Reductase